Patents by Inventor John P. Geibel
John P. Geibel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11510894Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: GrantFiled: January 25, 2007Date of Patent: November 29, 2022Inventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20200345767Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: February 19, 2020Publication date: November 5, 2020Inventors: John P. Geibel, Philipp Kirchhoff
-
Patent number: 10603339Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: GrantFiled: September 21, 2018Date of Patent: March 31, 2020Assignee: YALE UNIVERSITYInventors: John P. Geibel, Philipp Kirchhoff
-
Patent number: 10278989Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, in particular, zinc chloride and zinc acetate, alone or optionally, in combinations with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, including acid secretion in the fundus (by inhibiting vacuolar H+-ATPase or H+/K+-ATPase) and upper body region of the stomach (by inhibiting H+/K+-ATPase), thus raising the pH of gastric juices in rapid fashion and decreasing the duration of stomach acid release during a secretagogue phase. This method is also directed to treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: GrantFiled: May 22, 2013Date of Patent: May 7, 2019Assignee: YALE UNIVERSITYInventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20190022139Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: September 21, 2018Publication date: January 24, 2019Inventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20170209489Abstract: The present invention relates to the discovery that a hydrated salt form of zinc exhibits enhanced activity in reducing the acidity of gastric juice in a subject in need when compared to typical zinc salts. According to the invention, a zinc salt hydrate may be used alone or in combination with an additional zinc salt hydrate. Optionally these zinc salt hydrate(s) may be combined with at least one additional zinc salt. The zinc salt hydrate may be further combined with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent or additional therapeutic agents for providing fast action with optional long duration effect in reducing gastric acid secretion. In addition, the proposed methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.Type: ApplicationFiled: March 31, 2015Publication date: July 27, 2017Inventor: John P. Geibel
-
Publication number: 20160066564Abstract: One embodiment of the invention provides a perfusion system including: a first circuit adapted and configured to circulate a first perfusate through a lumen of a small intestine and a second circuit adapted and configured to circulate a second perfusate through one or more blood vessels of the small intestine. Another aspect of the invention provides a method of perfusing at least a portion of a small intestine. The method includes: circulating a first perfusate through a lumen of the small intestine and circulating a second perfusate through a blood vessel of the small intestine.Type: ApplicationFiled: March 31, 2015Publication date: March 10, 2016Inventors: John P. Geibel, Joseph Zinter, Manuel Rodriguez-Davalos, Roger Patron-Lozano, Spencer Backus, Andrew Crouch, Brian Loeb, Raja Narayan, Kristi Oki, Natalie Pancer
-
Publication number: 20150231175Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: March 4, 2015Publication date: August 20, 2015Inventors: John P. Geibel, Philipp Kirchhoff
-
Patent number: 9034391Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: GrantFiled: July 22, 2008Date of Patent: May 19, 2015Assignee: YALE UNIVERSITYInventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20140154339Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, in particular, zinc chloride and zinc acetate, alone or optionally, in combinations with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, including acid secretion in the fundus (by inhibiting vacuolar H+-ATPase or H+/K+-ATPase) and upper body region of the stomach (by inhibiting H+/K+-ATPase), thus raising the pH of gastric juices in rapid fashion and decreasing the duration of stomach acid release during a secretagogue phase. This method is also directed to treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: May 22, 2013Publication date: June 5, 2014Inventors: John P. Geibel, Phillipp Kirchhoff
-
Patent number: 8512761Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, in particular, zinc chloride and zinc acetate alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2-blocker, cytoprotective agent or a combination of agents as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, including acid secretion in the fundus (by inhibiting vacuolar H+-ATPase or H+/K+-ATPase) and upper body region of the stomach (by inhibiting H+/K+-ATPase), thus raising the pH of gastric juices in rapid fashion and decreasing the duration of stomach acid release during a secretagogue phase. The method is also directed to treating conditions including gastroesophogeal reflux disease, non-erosive reflux disease, Zollinger-Ellison syndrome, ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: GrantFiled: July 26, 2007Date of Patent: August 20, 2013Assignee: Yale UniversityInventors: John P Geibel, Philipp Kirchhoff
-
Publication number: 20100150861Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: July 22, 2008Publication date: June 17, 2010Applicant: YALE UNIVERSITYInventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20090035393Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: January 25, 2007Publication date: February 5, 2009Inventors: John P. Geibel, Philipp Kirchhoff